3 TEDA Projects Selected as Tianjin Major BioTech Special Projects
Tianjin Municipal Science and Technology Bureau recently announced the List of Proposed Projects for Tianjin 2024 Major Biomedicine Technology Special Projects, with three enterprises from TEDA on the list. Among them, CanSino Biologics was selected for the Phase II/III Clinical Trial Research of the Adjuvanted Acellular DTP Combined Innovative Vaccine for Adolescents and Adults under the Research on Chemical Drugs and Biological Products sub-project.
Century Healthcare was selected for the World's First Multi-level Depth-extended Artificial Lens under the Accelerating the Industrialization of Products in the National Innovation Medical Devices Catalog sub-project. DexBio was selected for the Smart Blood Transfusion Testing Production Line and Microfluidic Series Reagent Cards Industrialization Project under the Supporting R&D of High-End Medical Devices sub-project.
Biomedicine, one of TEDA's pillars, has witnessed growing scale in recent years, and has been recognized as one of China's earliest national-level strategic emerging industry clusters. TEDA is now home to over 400 biomedicine enterprises, more than 30 provincial-level or higher research institutes, and 15 biomedicine platforms like incubators.
The clustering development of the industry has become increasingly prominent. Going forward, TEDA will continue to develop the 7 major industrial chains of drug R&D and manufacturing, high-end medical devices, biomedicine CXO, pet economy, bay area economy, food and biomanufacturing. TEDA will take proactive efforts to build platforms, strengthen policy support, and promote the high-quality development of the biomedicine sector.
First, please LoginComment After ~